AKP 11

Drug Profile

AKP 11

Alternative Names: AKP-11

Latest Information Update: 16 Feb 2017

Price : $50

At a glance

  • Originator Akaal Pharma
  • Class Anti-inflammatories; Antipsoriatics; Small molecules
  • Mechanism of Action Sphingosine 1 phosphate receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Plaque psoriasis
  • Phase I Atopic dermatitis; Rheumatoid arthritis
  • Preclinical Actinic keratosis; Crohn's disease; Multiple sclerosis; Ulcerative colitis

Most Recent Events

  • 15 Jan 2017 Akaal Pharma completes a phase I trial in Atopic dermatitis in Australia (ACTRN12616000294459)
  • 24 Aug 2016 Akaal Pharma plans a phase II trial for Atopic dermatitis (Akaal Pharma website, August 2016)
  • 01 Aug 2016 Akaal Pharma completes a phase I trial in Rheumatoid arthritis in Australia (Topical) (ACTRN12616000922471)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top